Cytonics
Jupiter, US · Founded 2006 · Florida corporation · 13 employees on LinkedIn
Find your way into Cytonics
Sign up to see every warm intro you have to Cytonics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cytonics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.
Founders & leadership

Reported raises · per SEC filings
Form D private placements$839K disclosed across 3 rounds · 2018–2019
▶$20KraisedJun 2019 · 1 investors · BiotechnologyRule 506(c)
- Joey BoseExecutive Officer
- Offering amount
- $450K
- Amount sold
- $20K
- Minimum investment
- $20K
- Sales commissions
- $1.5K
- Placement agents
- SI Securities, LLC
- First sale
- Jun 2019
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06c
▶$25KraisedJun 2019 · 1 investors · BiotechnologyRule 506(c)
- Joey BoseExecutive Officer
- Offering amount
- $450K
- Amount sold
- $25K
- Minimum investment
- $20K
- Sales commissions
- $1.9K
- Placement agents
- SI Securities, LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06c
▶$794KraisedDec 2018 · 20 investors · BiotechnologyRule 506(c)
- Joey BoseExecutive Officer
- Offering amount
- $1M
- Amount sold
- $794K
- Minimum investment
- $25K
- First sale
- Jun 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Cytonics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $192.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Cytonics do?
- Cytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.
- How much funding has Cytonics raised?
- Cytonics has disclosed $839K raised across 3 rounds.
- Where is Cytonics headquartered?
- Cytonics is headquartered in Jupiter, US.




